Hospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (78)

2023

  1. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment

    European Journal of Surgical Oncology, Vol. 49, Núm. 10

2021

  1. Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments

    Journal of Surgical Oncology, Vol. 123, Núm. 1, pp. 71-79

  2. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

  3. The ESSO core curriculum committee update on surgical oncology

    European Journal of Surgical Oncology, Vol. 47, Núm. 11, pp. e1-e30

  4. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. A randomized study comparing different doses of superparamagnetic iron oxide tracer for sentinel lymph node biopsy in breast cancer: The SUNRISE study

    European Journal of Surgical Oncology, Vol. 46, Núm. 12, pp. 2195-2201

  2. Axillary staging based on molecular analysis: Results of the B-CLOSER-II study

    Pathology Research and Practice, Vol. 216, Núm. 11

  3. Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

    Frontiers in Oncology, Vol. 10

  4. Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial

    Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197

2019

  1. Learning curves in intraoperative ultrasound guided surgery in breast cancer based on complete breast cancer excision and no need for second surgeries

    European Journal of Surgical Oncology, Vol. 45, Núm. 4, pp. 578-583

  2. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

    Oncologist, Vol. 24, Núm. 5, pp. 603-611

  3. Percutaneous ultrasound-guided vacuum-assisted excision of benign breast lesions: A learning curve to assess outcomes

    British Journal of Radiology, Vol. 92, Núm. 1094

2018

  1. A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer

    Clinical Breast Cancer, Vol. 18, Núm. 4, pp. e613-e619

  2. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  3. Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

    Annals of Oncology, Vol. 29, Núm. 2, pp. 405-417

  4. P95HER2–T cell bispecific antibody for breast cancer treatment

    Science Translational Medicine, Vol. 10, Núm. 461

  5. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210

  6. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis

    Cancer, Vol. 124, Núm. 14, pp. 2923-2930

  7. Variations in the opinion of breast surgeons and radiation oncologist regarding indications for radiation therapy after NSM: The need for prospective studies

    European Journal of Surgical Oncology

2017

  1. Breast implant associated anaplastic large cell lymphoma: Impact and implications

    European Journal of Surgical Oncology